Vulvovaginal Candidiasis Therapeutic Pipeline and Development Review H1 2015 Research Report

DALLAS, March 23, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Vulvovaginal Candidiasis - Pipeline Review, H1 2015" therapeutic market research report of 48 pages with latest updates, data and information to its online business intelligence library.

The report "Vulvovaginal Candidiasis - Pipeline Review, H1 2015 provides comprehensive information on the therapeutic development for Vulvovaginal Candidiasis. Vulvovaginal candidiasis (VVC) is occurs when there is overgrowth of the normal yeast in the vagina. Most women notice from time to time that they have a discharge from the vagina. As many as 3 out of 4 women experience a yeast infection at some point in their lifetimes. Many women experience two or more yeast infections. Too much yeast in vagina can lead to vaginal itching, burning and other classic signs and symptoms of a yeast infection. A yeast infection can be sexually transmitted, especially through oral-genital sexual contact.

This report is complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vulvovaginal Candidiasis and special features on late-stage and discontinued projects.

Companies discussed in this report include:

• Actavis plc
• Grupo Ferrer Internacional, S.A.
• NovaDigm Therapeutics, Inc.
• Viamet Pharmaceuticals, Inc.

Drug Profiles in this report include albaconazole, arasertaconazole, NDV-3, NDV-3A, PEV-7, VT-1161. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310190 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report includes: Sep 10, 2014: Data for Viamet's VT-1161 Presented at ICAAC 2014; Jul 10, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Study of VT-1161 in Patients with Moderate to Severe Acute Vulvovaginal Candidiasis; Feb 18, 2014: Viamet Reports Positive Interim Results of Phase 2 Study of VT-1161; Sep 24, 2013: Viamet Pharmaceuticals Expands Phase 2 Clinical Program with Novel Antifungal Agent VT-1161; Sep 05, 2013: Viamet Pharmaceuticals Initiates Phase 2 Clinical Program with Novel Antifungal Agent VT-1161; Aug 08, 2012: Ferrer Submits IND For Arasertaconazole Nitrate For Vulvovaginal Candidiasis; Jan 17, 2012: Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory In All Vaccinees; Oct 11, 2011: Pevion's Therapeutic Candida Vaccine PEV7 Shows Robust Systemic And Mucosal Immunogenicity; Sep 01, 2011: Pevion Grants CSL Option Right To Therapeutic Candida Vaccine; Nov 11, 2010: Pevion Announces Positive Preliminary Results From Phase I Study Of PEV7 In Recurrent Vulvovaginal Candidiasis.

The scope of the report ranges from global therapeutic landscape of Vulvovaginal Candidiasis to the recent news and deals undertaken in the field of pipeline review. There is a detailed assessment of monotherapy and combination therapy pipeline projects along with a products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The person referring to the report will be able to devise his R&D development strategies as it includes significant competitor information, analysis and valuable insights. The report mentions the new entrants to the market and the emerging players. The report also helps in developing and designing in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Explore more reports on Infectious Diseases Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics .

More reports on Infectious Diseases Therapeutics:

Poxvirus Infections - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Poxvirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report include BioApex, s.r.o., China Biologic Products, Inc., SIGA Technologies, Inc., Takeda Pharmaceutical Company Limited. Complete report available at http://www.rnrmarketresearch.com/poxvirus-infections-pipeline-review-h1-2015-market-report.html .

Arenavirus Infection Lassa Fever - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Arenavirus Infection Lassa Fever. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. Companies discussed in this report include Profectus BioSciences, Inc., SIGA Technologies, Inc. Complete report available at http://www.rnrmarketresearch.com/arenavirus-infection-lassa-fever-pipeline-review-h1-2015-market-report.html .

Epstein-Barr Viral Infections - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Epstein-Barr Viral Infections. Companies discussed in this report include Cell Medica Limited, Epiphany Biosciences, Inc., Theravectys S.A., ViroStatics, srl. Complete report available at http://www.rnrmarketresearch.com/epstein-barr-viral-infections-pipeline-review-h1-2015-market-report.html .

Francisella Tularensis Infections - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Francisella Tularensis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development are Aradigm Corporation, EpiVax, Inc., Evolva SA, Tetraphase Pharmaceuticals Inc. Complete report available at http://www.rnrmarketresearch.com/francisella-tularensis-infections-pipeline-review-h1-2015-market-report.html .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com